WHO ICTRP trial
Theranostics: 68GaDOTATOC and 90YDOTATOC
NCT02441088 · NIH Clinical Trials · Not recruiting
Key facts
| Trial ID | NCT02441088 |
|---|---|
| Public title | Theranostics: 68GaDOTATOC and 90YDOTATOC |
| Scientific title | Dosimetry-Guided 90Y-DOTA-tyr3-Octreotide (90Y-DOTATOC) Peptide Receptor Radiotherapy (PRRT) in Children & Adults With Neuroendocrine and Other Somatostatin Receptor Expressing Tumors Determined by 68Ga-DOTA-tyr3-Octreotide (68Ga-DOTATOC) PET |
| Acronym | PRRT |
| Primary sponsor | Sue O'Dorisio |
| Secondary sponsors | National Institutes of Health (NIH);National Cancer Institute (NCI) |
| Registry | NIH Clinical Trials |
| Recruitment status | Not recruiting |
| Study type | Interventional |
| Phase | Phase 2 |
| Countries | United States |
| Conditions | Neuroendocrine Tumors;Carcinoid Tumors;Neuroblastoma;Medulloblastoma |
| Interventions | Drug: 90Y-DOTA-tyr3-Octreotide;Radiation: Dosimetry-Guided Peptide Receptor Radiotherapy;Drug: Aminosyn II |
| Registration date | Jan 5, 2015 |
| Target size | 25 |
| Secondary IDs | R01CA167632;201708778;201412770 |
| Registry page | clinicaltrials.gov |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: